- Asad Haider is managing director at Goldman Sachs, leads US pharma coverage
Goldman Sachs analyst Asad Haider is constructive on large-cap pharma, naming Eli Lilly, Johnson & Johnson, and Merck as top picks. He cites product-cycle momentum, pipeline strength, and M&A capacity. Biotech faces headwinds from rate hikes and election uncertainty.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.